On 13 January, The US Food and Drug Administration (FDA) expanded the approved usage for Gore’s TAG Thoracic Endoprosthesis to include treatment of life-threatening tears or thoracic aortic transection.
Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the Esprit drug-eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries and iliac arteries that have resulted in claudication (leg pain upon walking).
AccuVein, creator of the AV300, the world’s only hand-held, non-contact vein illumination device, announced that to date it has sold and installed 64 units to Banner Health, one of the largest nonprofit healthcare systems in the USA.
A study published in October in the Journal of Endovascular Therapy has found that Zilver PTX (Cook Medical) drug-eluting stent is safe for treatment of patients with de novo and restenotic lesions of the above-the-knee femoropopliteal segment.
Lammer from the University Hospital Vienna, Austria, said that the preliminary data from the VIASTAR trial show a trend towards a higher instent restenosis/occlusion rate with bare metal stents. However, he noted that edge restenosis of the Viabahn (Gore) endoprostheses can still be seen.
The US Food and Drug Administration FDA has approved the Conformable Gore Tag thoracic endoprosthesis (Gore) as a minimally invasive treatment for patients suffering from thoracic aortic aneurysms (TAAs).
On 21 November, the US Food and Drug Administration (FDA) gave 510(k) clearance to Aptus Endosystems for its EndoStapling system, which will be known as the HeliFX Aortic Securement System. According to the FDA this is the first system used to repair a failed aortic endograft.
Five-year data from the THU"DER trial demonstrated a 59% relative reduction in target lesion revascularisation rates in popliteal arteries of patients with peripheral arterial disease (PAD) treated with the Cotavance drug-eluting balloon (Medrad) with Paccocath technology compared to standard balloon angioplasty. Additionally, for patients requiring target lesion revascularisation, the average time to revascularisation before target lesion revascularisation was extended by 448 days in patients treated with the Cotavance catheter.
Boston Scientific reports positive outcomes from the CABANA post-approval study of the Carotid Wallstent Monorail Endoprosthesis used in conjunction with its FilterWire EZ embolic protection system in routine clinical practice.
Boston Scientific launched its Coyote balloon catheter, a highly deliverable and ultra-low profile 0.014 inch balloon dilatation catheter designed to treat patients undergoing peripheral angioplasty procedures below the knee. The company has begun marketing the product in the USA, Europe and other international markets.
The US Food and Drug Administration has approved the Ovation abdominal stent graft system (TriVascular) under a humanitarian device exemption (HDE). According to TriVascular, this is the first HDE granted by the FDA in the field of abdominal aortic aneurysm treatment. With this approval, patients previously ineligible for EVAR will gain access to a minimally invasive therapy.
Medtronic has announced FDA approval of the Assurant cobalt iliac balloonexpandable stent system. The new device features the first balloon-expandable stent made from a cobalt-chromium alloy to be approved by the FDA for the treatment of narrowed iliac arteries. It complements Medtronic’s self-expanding Complete SE Vascular Stent, which is already approved with an iliac indication.
BIOTRONIK AG, fabricante líder de dispositivos vasculares para tratamientos intervencionistas, anunció el lanzamiento de una ampliación de su popular línea del sistema de stents autoexpandibles, compatibles con 4 F, dedicada al tratamiento de segmentos largos en la arteriopatía femoral superficial (AFS) y en las arterias infrapoplíteas. Con este lanzamiento, BIOTRONIK destaca frente a sus competidores y se convierte en la única empresa del mundo que ofrece un paquete completo de productos para intervención periférica con "soluciones 4 F" para el tratamiento de arteriopatías de los miembros inferiores.
Trabajo presentado en el I Curso de Medicina Vascular de la SEACV. La Dra. Morata Barrado es miembro del Servicio de Angiología, Cirugía Vascular y Endovascular del Hospital Universitario de Guadalajara.
Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the Esprit drug-eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries and iliac arteries that have resulted in claudication (leg pain upon walking).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos